Humphreys RE[au] - Search Results

Year	Number of Results
1964	1
1968	1
1972	1
1974	2
1975	3
1976	6
1977	2
1978	2
1979	5
1980	3
1981	6
1982	1
1983	3
1984	7
1985	4
1986	1
1987	6
1988	4
1989	7
1990	6
1991	12
1992	7
1993	7
1994	4
1995	2
1996	1
1997	2
1999	2
2000	2
2001	1
2002	1
2003	3
2004	4
2005	2
2006	4
2007	2
2010	1
2014	1
2022	0

1

Low-flow mediated constriction: the yin to FMD's yang?

Humphreys RE, Green DJ, Cable NT, Thijssen DH, Dawson EA. Humphreys RE, et al. Expert Rev Cardiovasc Ther. 2014 May;12(5):557-64. doi: 10.1586/14779072.2014.909728. Epub 2014 Apr 18. Expert Rev Cardiovasc Ther. 2014. PMID: 24745959 Review.

2

Genetic modulation of tumor antigen presentation.

Xu M, Qiu G, Jiang Z, von Hofe E, Humphreys RE. Xu M, et al. Among authors: humphreys re. Trends Biotechnol. 2000 Apr;18(4):167-72. doi: 10.1016/s0167-7799(00)01421-9. Trends Biotechnol. 2000. PMID: 10740263 Review.

3

Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease.

Kallinteris NL, Powell D, Blackwell CE, Kim M, Lu X, Wu S, Humphreys RE, Xu M, von Hofe E. Kallinteris NL, et al. Among authors: humphreys re. Front Biosci. 2006 Jan 1;11:46-58. doi: 10.2741/1779. Front Biosci. 2006. PMID: 16146713 Review.

4

Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.

Kallinteris NL, Lu X, Blackwell CE, von Hofe E, Humphreys RE, Xu M. Kallinteris NL, et al. Among authors: humphreys re. Expert Opin Biol Ther. 2006 Dec;6(12):1311-21. doi: 10.1517/14712598.6.12.1311. Expert Opin Biol Ther. 2006. PMID: 17223739 Review.

5

Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.

Hillman GG, Kallinteris NL, Lu X, Wang Y, Wright JL, Li Y, Wu S, Forman JD, Gulfo JV, Humphreys RE, Xu M. Hillman GG, et al. Among authors: humphreys re. Cancer Treat Rev. 2004 May;30(3):281-90. doi: 10.1016/j.ctrv.2003.08.002. Cancer Treat Rev. 2004. PMID: 15059651 Review.

6

MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases.

Xu M, Li J, Gulfo JV, Von Hofe E, Humphreys RE. Xu M, et al. Among authors: humphreys re. Scand J Immunol. 2001 Jul-Aug;54(1-2):39-44. doi: 10.1046/j.1365-3083.2001.00964.x. Scand J Immunol. 2001. PMID: 11439146 Free article. Review.

7

Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.

Humphreys RE, Hillman GG, von Hofe E, Xu M. Humphreys RE, et al. Cell Mol Immunol. 2004 Jun;1(3):180-5. Cell Mol Immunol. 2004. PMID: 16219165 Free article. Review.

8

The immunoglobulin-like structure of human histocompatibility antigens.

Strominger JL, Cresswell P, Grey H, Humphreys RE, Mann D, McCuneJ, Parham P, Robb R, Sanderson AR, Springer TA, Terhorst C, Turner MJ. Strominger JL, et al. Among authors: humphreys re. Transplant Rev. 1974;21(0):126-43. doi: 10.1111/j.1600-065x.1974.tb01549.x. Transplant Rev. 1974. PMID: 4139785 Review. No abstract available.

9

Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies.

Kallinteris NL, Wu S, Lu X, von Hofe E, Humphreys RE, Xu M. Kallinteris NL, et al. Among authors: humphreys re. Vaccine. 2005 Mar 18;23(17-18):2336-8. doi: 10.1016/j.vaccine.2005.01.038. Vaccine. 2005. PMID: 15755623

10

Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.

Lu X, Wu S, Blackwell CE, Humphreys RE, von Hofe E, Xu M. Lu X, et al. Among authors: humphreys re. Immunology. 2007 Feb;120(2):207-16. doi: 10.1111/j.1365-2567.2006.02492.x. Epub 2006 Nov 20. Immunology. 2007. PMID: 17116173 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results